These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36463835)

  • 1. Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab.
    Camelo RM; Barbosa MM; Araújo MS; Muniz RL; Guerra AA; Godman B; Rezende SM; Acurcio FA; Martin AP; Alvares-Teodoro J
    Value Health Reg Issues; 2023 Mar; 34():31-39. PubMed ID: 36463835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
    Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
    Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
    Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
    Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 10. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
    Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
    Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
    Earnshaw SR; Graham CN; McDade CL; Spears JB; Kessler CM
    Haemophilia; 2015 May; 21(3):310-319. PubMed ID: 25688580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
    Matsushita T; Suzuki N; Nagao A; Nagae C; Yamaguchi-Suita H; Kyogoku Y; Ioka A; Nogami K
    BMJ Open; 2022 Mar; 12(3):e057018. PubMed ID: 35288393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein K; Le Quellec S; Klamroth R; Batorova A; Holme PA; Jiménez-Yuste V; Astermark J
    Haemophilia; 2022 Mar; 28(2):215-222. PubMed ID: 34918839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update.
    Hart DP; Alamelu J; Bhatnagar N; Biss T; Collins PW; Hall G; Hay C; Liesner R; Makris M; Mathias M; Motwani J; Palmer B; Payne J; Percy C; Richards M; Riddell A; Talks K; Tunstall O; Chalmers E
    Haemophilia; 2021 Nov; 27(6):932-937. PubMed ID: 34403546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
    Carcao M; Escuriola-Ettingshausen C; Santagostino E; Oldenburg J; Liesner R; Nolan B; Bátorová A; Haya S; Young G;
    Haemophilia; 2019 Jul; 25(4):676-684. PubMed ID: 31033112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes.
    Levy-Mendelovich S; Atia N; Budnik I; Barg AA; Avishai E; Cohen O; Brutman-Barazani T; Livnat T; Kenet G
    Res Pract Thromb Haemost; 2023 May; 7(4):100278. PubMed ID: 37538499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
    Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
    Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.